Top

Journal of Cardiovascular Translational Research

Published in:

01-08-2012

Chromatin Modifications Associated with Diabetes

Authors: Samuel T. Keating, Assam El-Osta

Published in: Journal of Cardiovascular Translational Research | Issue 4/2012

Abstract

Accelerated rates of vascular complications are associated with diabetes mellitus. Environmental factors including hyperglycaemia contribute to the progression of diabetic complications. Epidemiological and experimental animal studies identified poor glycaemic control as a major contributor to the development of complications. These studies suggest that early exposure to hyperglycaemia can instigate the development of complications that present later in the progression of the disease, despite improved glycaemic control. Recent experiments reveal a striking commonality associated with gene-activating hyperglycaemic events and chromatin modification. The best characterised to date are associated with the chemical changes of amino-terminal tails of histone H3. Enzymes that write specified histone tail modifications are not well understood in models of hyperglycaemia and metabolic memory as well as human diabetes. The best-characterised enzyme is the lysine specific Set7 methyltransferase. The contribution of Set7 to the aetiology of diabetic complications may extend to other transcriptional events through methylation of non-histone substrates.

International Diabetes Federation. (2009). IDF diabetes atlas (4th ed.). Brussels: International Diabetes Federation.

Shaw, J. E., & Chisholm, D. J. (2003). 1: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. The Medical Journal of Australia, 179(7), 379–383.PubMed

El-Osta, A. (2012). Glycemic memory. Current Opinion in Lipidology, 23(1), 24–29.PubMedCrossRef

Brownlee, M. (2001). Biochemistry and molecular cell biology of diabetic complications. Nature, 414(6865), 813–820.PubMedCrossRef

Anonymous (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. New England Journal of Medicine, 329(14), 977–986.

Prospective, U. K. (1991). Diabetes study (UKPDS). VIII. Study design, progress and performance. Diabetologia, 34(12), 877–890.CrossRef

The Diabetes Control and Complications Trial (DCCT). (1986). Design and methodologic considerations for the feasibility phase. The DCCT research group. Diabetes, 35(5), 530–545.CrossRef

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. (2003). Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA, 290(16), 2159–2167.CrossRef

Nathan, D. M., Cleary, P. A., Backlund, J. Y., et al. (2005). Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. The New England Journal of Medicine, 353(25), 2643–2653.PubMedCrossRef

10.

Cleary, P. A., Orchard, T. J., Genuth, S., et al. (2006). The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes, 55(12), 3556–3565.PubMedCrossRef

11.

Nathan, D. M., Lachin, J., Cleary, P., et al. (2003). Intensive diabetes therapy and carotid intima–media thickness in type 1 diabetes mellitus. The New England Journal of Medicine, 348(23), 2294–2303.PubMedCrossRef

12.

Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. The New England Journal of Medicine, 359(15), 1577–1589.PubMedCrossRef

13.

Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. (2002). Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA, 287(19), 2563–2569.CrossRef

14.

Engerman, R. L., & Kern, T. S. (1987). Progression of incipient diabetic retinopathy during good glycemic control. Diabetes, 36(7), 808–812.PubMedCrossRef

15.

Hammes, H. P., Klinzing, I., Wiegand, S., Bretzel, R. G., Cohen, A. M., & Federlin, K. (1993). Islet transplantation inhibits diabetic retinopathy in the sucrose-fed diabetic Cohen rat. Investigative Ophthalmology & Visual Science, 34(6), 2092–2096.

16.

Kowluru, R. A. (2003). Effect of reinstitution of good glycemic control on retinal oxidative stress and nitrative stress in diabetic rats. Diabetes, 52(3), 818–823.PubMedCrossRef

17.

El-Osta, A., Brasacchio, D., Yao, D., et al. (2008). Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. The Journal of Experimental Medicine, 205(10), 2409–2417.PubMedCrossRef

18.

Thurberg, B. L., & Collins, T. (1998). The nuclear factor-kappa B/inhibitor of kappa B autoregulatory system and atherosclerosis. Current Opinion in Lipidology, 9(5), 387–396.PubMedCrossRef

19.

Lewis, P., Stefanovic, N., Pete, J., et al. (2007). Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation, 115(16), 2178–2187.PubMedCrossRef

20.

Bakker, W., Eringa, E. C., Sipkema, P., & van Hinsbergh, V. W. (2009). Endothelial dysfunction and diabetes: roles of hyperglycemia, impaired insulin signaling and obesity. Cell and Tissue Research, 335(1), 165–189.PubMedCrossRef

21.

Roy, S., Sala, R., Cagliero, E., & Lorenzi, M. (1990). Overexpression of fibronectin induced by diabetes or high glucose: phenomenon with a memory. Proceedings of the National Academy of Sciences of the United States of America, 87(1), 404–408.PubMedCrossRef

22.

Nishikawa, T., Edelstein, D., Du, X. L., et al. (2000). Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature, 404(6779), 787–790.PubMedCrossRef

23.

Brownlee, M. (2005). The pathobiology of diabetic complications: a unifying mechanism. Diabetes, 54(6), 1615–1625.PubMedCrossRef

24.

Ihnat, M. A., Thorpe, J. E., Kamat, C. D., et al. (2007). Reactive oxygen species mediate a cellular ‘memory’ of high glucose stress signalling. Diabetologia, 50(7), 1523–1531.PubMedCrossRef

25.

Turner, B. M. (2002). Cellular memory and the histone code. Cell, 111(3), 285–291.PubMedCrossRef

26.

Bird, A. (2007). Perceptions of epigenetics. Nature, 447(7143), 396–398.PubMedCrossRef

27.

Jenuwein, T., & Allis, C. D. (2001). Translating the histone code. Science, 293(5532), 1074–1080.PubMedCrossRef

28.

Greer, E. L., Maures, T. J., Ucar, D., et al. (2011). Transgenerational epigenetic inheritance of longevity in Caenorhabditis elegans. Nature, 479(7373), 365–371.PubMedCrossRef

29.

Braunschweig, M., Jagannathan, V., Gutzwiller, A., & Bee, G. (2012). Investigations on transgenerational epigenetic response down the male line in f2 pigs. PLoS One, 7(2), e30583.PubMedCrossRef

30.

Iguchi-Ariga, S. M., & Schaffner, W. (1989). CpG methylation of the cAMP-responsive enhancer/promoter sequence TGACGTCA abolishes specific factor binding as well as transcriptional activation. Genes & Development, 3(5), 612–619.CrossRef

31.

Pennings, S., Allan, J., & Davey, C. S. (2005). DNA methylation, nucleosome formation and positioning. Briefings in Functional Genomics & Proteomics, 3(4), 351–361.CrossRef

32.

Chodavarapu, R. K., Feng, S., Bernatavichute, Y. V., et al. (2010). Relationship between nucleosome positioning and DNA methylation. Nature, 466(7304), 388–392.PubMedCrossRef

33.

Fuks, F., Hurd, P. J., Wolf, D., Nan, X., Bird, A. P., & Kouzarides, T. (2003). The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. Journal of Biological Chemistry, 278(6), 4035–4040.PubMedCrossRef

34.

Meehan, R. R., Lewis, J. D., & Bird, A. P. (1992). Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Research, 20(19), 5085–5092.PubMedCrossRef

35.

Zhang, Y., Ng, H. H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999). Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes & Development, 13(15), 1924–1935.CrossRef

36.

Maier, S., & Olek, A. (2002). Diabetes: a candidate disease for efficient DNA methylation profiling. Journal of Nutrition, 132(8 Suppl), 2440S–2443S.PubMed

37.

Reik, W., Dean, W., & Walter, J. (2001). Epigenetic reprogramming in mammalian development. Science, 293(5532), 1089–1093.PubMedCrossRef

38.

Thompson, R. F., Fazzari, M. J., Niu, H., Barzilai, N., Simmons, R. A., & Greally, J. M. (2010). Experimental intrauterine growth restriction induces alterations in DNA methylation and gene expression in pancreatic islets of rats. Journal of Biological Chemistry, 285(20), 15111–15118.PubMedCrossRef

39.

Einstein, F., Thompson, R. F., Bhagat, T. D., et al. (2010). Cytosine methylation dysregulation in neonates following intrauterine growth restriction. PLoS One, 5(1), e8887.PubMedCrossRef

40.

Kuroda, A., Rauch, T. A., Todorov, I., et al. (2009). Insulin gene expression is regulated by DNA methylation. PLoS One, 4(9), e6953.PubMedCrossRef

41.

Stenvinkel, P., Karimi, M., Johansson, S., et al. (2007). Impact of inflammation on epigenetic DNA methylation—a novel risk factor for cardiovascular disease? Journal of Internal Medicine, 261(5), 488–499.PubMedCrossRef

42.

Brennan, E. P., Ehrich, M., O’Donovan, H., et al. (2010). DNA methylation profiling in cell models of diabetic nephropathy. Epigenetics, 5(5), 396–401.PubMedCrossRef

43.

Chan, Y., Fish, J. E., D’Abreo, C., et al. (2004). The cell-specific expression of endothelial nitric-oxide synthase: a role for DNA methylation. Journal of Biological Chemistry, 279(33), 35087–35100.PubMedCrossRef

44.

Bell, C. G., Teschendorff, A. E., Rakyan, V. K., Maxwell, A. P., Beck, S., & Savage, D. A. (2010). Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 diabetes mellitus. BMC Medical Genomics, 3, 33.PubMedCrossRef

45.

Kim, M., Long, T. I., Arakawa, K., Wang, R., Yu, M. C., & Laird, P. W. (2010). DNA methylation as a biomarker for cardiovascular disease risk. PLoS One, 5(3), e9692.PubMedCrossRef

46.

Hiltunen, M. O., Turunen, M. P., Hakkinen, T. P., et al. (2002). DNA hypomethylation and methyltransferase expression in atherosclerotic lesions. Vascular Medicine, 7(1), 5–11.PubMedCrossRef

47.

Hiltunen, M. O., & Yla-Herttuala, S. (2003). DNA methylation, smooth muscle cells, and atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 23(10), 1750–1753.PubMedCrossRef

48.

Laukkanen, M. O., Mannermaa, S., Hiltunen, M. O., et al. (1999). Local hypomethylation in atherosclerosis found in rabbit ec-sod gene. Arteriosclerosis, Thrombosis, and Vascular Biology, 19(9), 2171–2178.PubMedCrossRef

49.

Rakyan, V. K., Beyan, H., Down, T. A., et al. (2011). Identification of type 1 diabetes-associated DNA methylation variable positions that precede disease diagnosis. PLoS Genetics, 7(9), e1002300.PubMedCrossRef

50.

Luger, K. (2006). Dynamic nucleosomes. Chromosome Research, 14(1), 5–16.PubMedCrossRef

51.

Strahl, B. D., & Allis, C. D. (2000). The language of covalent histone modifications. Nature, 403(6765), 41–45.PubMedCrossRef

52.

Malik, H. S., & Henikoff, S. (2003). Phylogenomics of the nucleosome. Natural Structural Biology, 10(11), 882–891.CrossRef

53.

Kouzarides, T. (2007). Chromatin modifications and their function. Cell, 128(4), 693–705.PubMedCrossRef

54.

An, W. (2007). Histone acetylation and methylation: combinatorial players for transcriptional regulation. Subcellular Biochemistry, 41, 351–369.PubMedCrossRef

55.

Roth, S. Y., Denu, J. M., & Allis, C. D. (2001). Histone acetyltransferases. Annual Review of Biochemistry, 70, 81–120.PubMedCrossRef

56.

Shogren-Knaak, M., Ishii, H., Sun, J. M., Pazin, M. J., Davie, J. R., & Peterson, C. L. (2006). Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science, 311(5762), 844–847.PubMedCrossRef

57.

Braunstein, M., Rose, A. B., Holmes, S. G., Allis, C. D., & Broach, J. R. (1993). Transcriptional silencing in yeast is associated with reduced nucleosome acetylation. Genes & Development, 7(4), 592–604.CrossRef

58.

Grunstein, M. (1997). Histone acetylation in chromatin structure and transcription. Nature, 389(6649), 349–352.PubMedCrossRef

59.

Eberharter, A., & Becker, P. B. (2002). Histone acetylation: a switch between repressive and permissive chromatin. Second in review series on chromatin dynamics. EMBO Reports, 3(3), 224–229.PubMedCrossRef

60.

Roh, T. Y., Cuddapah, S., & Zhao, K. (2005). Active chromatin domains are defined by acetylation islands revealed by genome-wide mapping. Genes & Development, 19(5), 542–552.CrossRef

61.

Roh, T. Y., Wei, G., Farrell, C. M., & Zhao, K. (2007). Genome-wide prediction of conserved and nonconserved enhancers by histone acetylation patterns. Genome Research, 17(1), 74–81.PubMedCrossRef

62.

de Ruijter, A. J., van Gennip, A. H., Caron, H. N., Kemp, S., & van Kuilenburg, A. B. (2003). Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochemistry Journal, 370(Pt 3), 737–749.

63.

Wade, P. A., & Wolffe, A. P. (1997). Histone acetyltransferases in control. Current Biology, 7(2), R82–R84.PubMedCrossRef

64.

Chen, S., Feng, B., George, B., Chakrabarti, R., Chen, M., & Chakrabarti, S. (2010). Transcriptional coactivator p300 regulates glucose-induced gene expression in endothelial cells. American Journal of Physiology, Endocrinology and Metabolism, 298(1), E127–E137.CrossRef

65.

Mosley, A. L., & Ozcan, S. (2003). Glucose regulates insulin gene transcription by hyperacetylation of histone h4. Journal of Biological Chemistry, 278(22), 19660–19666.PubMedCrossRef

66.

Mosley, A. L., Corbett, J. A., & Ozcan, S. (2004). Glucose regulation of insulin gene expression requires the recruitment of p300 by the beta-cell-specific transcription factor Pdx-1. Molecular Endocrinology, 18(9), 2279–2290.PubMedCrossRef

67.

Suganuma, T., & Workman, J. L. (2011). Signals and combinatorial functions of histone modifications. Annual Review of Biochemistry, 80, 473–499.PubMedCrossRef

68.

Cheung, P., & Lau, P. (2005). Epigenetic regulation by histone methylation and histone variants. Molecular Endocrinology, 19(3), 563–573.PubMedCrossRef

69.

Zhang, Y., & Reinberg, D. (2001). Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes & Development, 15(18), 2343–2360.CrossRef

70.

Qian, C., & Zhou, M. M. (2006). SET domain protein lysine methyltransferases: structure, specificity and catalysis. Cellular and Molecular Life Sciences, 63(23), 2755–2763.PubMedCrossRef

71.

Tschiersch, B., Hofmann, A., Krauss, V., Dorn, R., Korge, G., & Reuter, G. (1994). The protein encoded by the Drosophila position-effect variegation suppressor gene Su(var)3–9 combines domains of antagonistic regulators of homeotic gene complexes. EMBO Journal, 13(16), 3822–3831.PubMed

72.

Stassen, M. J., Bailey, D., Nelson, S., Chinwalla, V., & Harte, P. J. (1995). The Drosophila trithorax proteins contain a novel variant of the nuclear receptor type DNA binding domain and an ancient conserved motif found in other chromosomal proteins. Mechanisms of Development, 52(2–3), 209–223.PubMedCrossRef

73.

Jenuwein, T., Laible, G., Dorn, R., & Reuter, G. (1998). SET domain proteins modulate chromatin domains in eu- and heterochromatin. Cellular and Molecular Life Sciences, 54(1), 80–93.PubMedCrossRef

74.

Sims, R. J., 3rd, Nishioka, K., & Reinberg, D. (2003). Histone lysine methylation: a signature for chromatin function. Trends in Genetics, 19(11), 629–639.PubMedCrossRef

75.

Boggs, B. A., Cheung, P., Heard, E., Spector, D. L., Chinault, A. C., & Allis, C. D. (2002). Differentially methylated forms of histone H3 show unique association patterns with inactive human X chromosomes. Nature Genetics, 30(1), 73–76.PubMedCrossRef

76.

Noma, K., Allis, C. D., & Grewal, S. I. (2001). Transitions in distinct histone H3 methylation patterns at the heterochromatin domain boundaries. Science, 293(5532), 1150–1155.PubMedCrossRef

77.

Syreeni, A., El-Osta, A., Forsblom, C., et al. (2011). Genetic examination of SETD7 and SUV39H1/H2 methyltransferases and the risk of diabetes complications in patients with type 1 diabetes. Diabetes, 60(11), 3073–3080.PubMedCrossRef

78.

Wang, H., Cao, R., Xia, L., et al. (2001). Purification and functional characterization of a histone H3-lysine 4-specific methyltransferase. Molecular Cell, 8(6), 1207–1217.PubMedCrossRef

79.

Nishioka, K., Chuikov, S., Sarma, K., et al. (2002). Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes & Development, 16(4), 479–489.CrossRef

80.

Zegerman, P., Canas, B., Pappin, D., & Kouzarides, T. (2002). Histone H3 lysine 4 methylation disrupts binding of nucleosome remodeling and deacetylase (NuRD) repressor complex. Journal of Biological Chemistry, 277(14), 11621–11624.PubMedCrossRef

81.

Deering, T. G., Ogihara, T., Trace, A. P., Maier, B., & Mirmira, R. G. (2009). Methyltransferase Set7/9 maintains transcription and euchromatin structure at islet-enriched genes. Diabetes, 58(1), 185–193.PubMedCrossRef

82.

Ogihara, T., Vanderford, N. L., Maier, B., Stein, R. W., & Mirmira, R. G. (2009). Expression and function of Set7/9 in pancreatic islets. Islets, 1(3), 269–272.PubMedCrossRef

83.

Francis, J., Chakrabarti, S. K., Garmey, J. C., & Mirmira, R. G. (2005). Pdx-1 links histone H3-Lys-4 methylation to RNA polymerase II elongation during activation of insulin transcription. Journal of Biological Chemistry, 280(43), 36244–36253.PubMedCrossRef

84.

Li, Y., Reddy, M. A., Miao, F., et al. (2008). Role of the histone H3 lysine 4 methyltransferase, SET7/9, in the regulation of NF-kappaB-dependent inflammatory genes. Relevance to diabetes and inflammation. Journal of Biological Chemistry, 283(39), 26771–26781.PubMedCrossRef

85.

Brasacchio, D., Okabe, J., Tikellis, C., et al. (2009). Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes, 58(5), 1229–1236.PubMedCrossRef

86.

Okabe, J., Orlowski, C., Balcerczyk, A., et al. (2012). Distinguishing hyperglycemic changes by Set7 in vascular endothelial cells. Circulation Research, 110, 1067–1076.PubMedCrossRef

87.

Ea, C. K., & Baltimore, D. (2009). Regulation of NF-kappaB activity through lysine monomethylation of p65. Proceedings of the National Academy of Sciences of the United States of America, 106(45), 18972–18977.PubMedCrossRef

88.

Yang, X. D., Huang, B., Li, M., Lamb, A., Kelleher, N. L., & Chen, L. F. (2009). Negative regulation of NF-kappaB action by Set9-mediated lysine methylation of the RelA subunit. EMBO Journal, 28(8), 1055–1066.PubMedCrossRef

89.

Sun, G., Reddy, M. A., Yuan, H., Lanting, L., Kato, M., & Natarajan, R. (2010). Epigenetic histone methylation modulates fibrotic gene expression. Journal of the American Society of Nephrology, 21(12), 2069–2080.PubMedCrossRef

90.

Verrecchia, F., Chu, M. L., & Mauviel, A. (2001). Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. Journal of Biological Chemistry, 276(20), 17058–17062.PubMedCrossRef

91.

Chung, A. C., Zhang, H., Kong, Y. Z., et al. (2010). Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling. Journal of the American Society of Nephrology, 21(2), 249–260.PubMedCrossRef

92.

Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., & Gauthier, J. M. (1998). Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO Journal, 17(11), 3091–3100.PubMedCrossRef

93.

Yang, F., Chung, A. C., Huang, X. R., & Lan, H. Y. (2009). Angiotensin II induces connective tissue growth factor and collagen I expression via transforming growth factor-beta-dependent and -independent Smad pathways: the role of Smad3. Hypertension, 54(4), 877–884.PubMedCrossRef

94.

Lan, H. Y. (2011). Diverse roles of TGF-beta/Smads in renal fibrosis and inflammation. International Journal of Biological Sciences, 7(7), 1056–1067.PubMedCrossRef

95.

Fujimoto, M., Maezawa, Y., Yokote, K., et al. (2003). Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochemical and Biophysical Research Communications, 305(4), 1002–1007.PubMedCrossRef

96.

Li, J. H., Huang, X. R., Zhu, H. J., et al. (2004). Advanced glycation end products activate Smad signaling via TGF-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease. The FASEB Journal, 18(1), 176–178.CrossRef

97.

Wang, W., Huang, X. R., Canlas, E., et al. (2006). Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circulation Research, 98(8), 1032–1039.PubMedCrossRef

98.

Martens, J. H., Verlaan, M., Kalkhoven, E., & Zantema, A. (2003). Cascade of distinct histone modifications during collagenase gene activation. Molecular and Cellular Biology, 23(5), 1808–1816.PubMedCrossRef

99.

Pradhan, S., Chin, H. G., Esteve, P. O., & Jacobsen, S. E. (2009). SET7/9 mediated methylation of non-histone proteins in mammalian cells. Epigenetics, 4(6), 383–387.PubMedCrossRef

100.

Dhayalan, A., Kudithipudi, S., Rathert, P., & Jeltsch, A. (2011). Specificity analysis-based identification of new methylation targets of the SET7/9 protein lysine methyltransferase. Chemical Biology, 18(1), 111–120.CrossRef

101.

Chuikov, S., Kurash, J. K., Wilson, J. R., et al. (2004). Regulation of p53 activity through lysine methylation. Nature, 432(7015), 353–360.PubMedCrossRef

102.

Esteve, P. O., Chin, H. G., Benner, J., et al. (2009). Regulation of DNMT1 stability through SET7-mediated lysine methylation in mammalian cells. Proceedings of the National Academy of Sciences of the United States of America, 106(13), 5076–5081.PubMedCrossRef

103.

Subramanian, K., Jia, D., Kapoor-Vazirani, P., et al. (2008). Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Molecular Cell, 30(3), 336–347.PubMedCrossRef

104.

Kouskouti, A., Scheer, E., Staub, A., Tora, L., & Talianidis, I. (2004). Gene-specific modulation of TAF10 function by SET9-mediated methylation. Molecular Cell, 14(2), 175–182.PubMedCrossRef

105.

Yang, J., Huang, J., Dasgupta, M., et al. (2010). Reversible methylation of promoter-bound STAT3 by histone-modifying enzymes. Proceedings of the National Academy of Sciences of the United States of America, 107(50), 21499–21504.PubMedCrossRef

106.

Saraheimo, M., Teppo, A. M., Forsblom, C., Fagerudd, J., & Groop, P. H. (2003). Diabetic nephropathy is associated with low-grade inflammation in type 1 diabetic patients. Diabetologia, 46(10), 1402–1407.PubMedCrossRef

107.

Shikano, M., Sobajima, H., Yoshikawa, H., et al. (2000). Usefulness of a highly sensitive urinary and serum IL-6 assay in patients with diabetic nephropathy. Nephron, 85(1), 81–85.PubMedCrossRef

108.

Tuttle, H. A., Davis-Gorman, G., Goldman, S., Copeland, J. G., & McDonagh, P. F. (2004). Proinflammatory cytokines are increased in type 2 diabetic women with cardiovascular disease. Journal of Diabetes and its Complications, 18(6), 343–351.PubMedCrossRef

109.

Mirza, S., Hossain, M., Mathews, C., et al. (2012). Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine, 57(1), 136–142.PubMedCrossRef

110.

Berthier, C. C., Zhang, H., Schin, M., et al. (2009). Enhanced expression of Janus kinase-signal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes, 58(2), 469–477.PubMedCrossRef

111.

Simon, A. R., Rai, U., Fanburg, B. L., & Cochran, B. H. (1998). Activation of the JAK-STAT pathway by reactive oxygen species. American Journal of Physiology, 275(6 Pt 1), C1640–C1652.PubMed

112.

Huang, J. S., Guh, J. Y., Chen, H. C., Hung, W. C., Lai, Y. H., & Chuang, L. Y. (2001). Role of receptor for advanced glycation end-product (RAGE) and the JAK/STAT-signaling pathway in AGE-induced collagen production in NRK-49F cells. Journal of Cellular Biochemistry, 81(1), 102–113.PubMedCrossRef

113.

Lu, T. C., Wang, Z. H., Feng, X., et al. (2009). Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney International, 76(1), 63–71.PubMedCrossRef

114.

Rawlings, J. S., Rosler, K. M., & Harrison, D. A. (2004). The JAK/STAT signaling pathway. Journal of Cell Science, 117(Pt 8), 1281–1283.PubMedCrossRef

115.

Yasukawa, H., Ohishi, M., Mori, H., et al. (2003). IL-6 induces an anti-inflammatory response in the absence of SOCS3 in macrophages. Nature Immunology, 4(6), 551–556.PubMedCrossRef

116.

Ortiz-Munoz, G., Lopez-Parra, V., Lopez-Franco, O., et al. (2010). Suppressors of cytokine signaling abrogate diabetic nephropathy. Journal of the American Society of Nephrology, 21(5), 763–772.PubMedCrossRef

117.

Gaughan, L., Stockley, J., Wang, N., et al. (2011). Regulation of the androgen receptor by SET9-mediated methylation. Nucleic Acids Research, 39(4), 1266–1279.PubMedCrossRef

118.

O’Meara, N. M., Blackman, J. D., Ehrmann, D. A., et al. (1993). Defects in beta-cell function in functional ovarian hyperandrogenism. Journal of Clinical Endocrinology and Metabolism, 76(5), 1241–1247.PubMedCrossRef

119.

Dunaif, A., & Finegood, D. T. (1996). beta-Cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. Journal of Clinical Endocrinology and Metabolism, 81(3), 942–947.PubMedCrossRef

120.

Liu, S., Navarro, G., & Mauvais-Jarvis, F. (2010). Androgen excess produces systemic oxidative stress and predisposes to beta-cell failure in female mice. PLoS One, 5(6), e11302.PubMedCrossRef

121.

Pirola, L., Balcerczyk, A., Tothill, R. W., et al. (2011). Genome-wide analysis distinguishes hyperglycemia regulated epigenetic signatures of primary vascular cells. Genome Research, 21(10), 1601–1615.PubMedCrossRef

122.

Giacco, F., & Brownlee, M. (2010). Oxidative stress and diabetic complications. Circulation Research, 107(9), 1058–1070.PubMedCrossRef

123.

Noyman, I., Marikovsky, M., Sasson, S., et al. (2002). Hyperglycemia reduces nitric oxide synthase and glycogen synthase activity in endothelial cells. Nitric Oxide, 7(3), 187–193.PubMedCrossRef

124.

Zhang, Q., Malik, P., Pandey, D., et al. (2008). Paradoxical activation of endothelial nitric oxide synthase by NADPH oxidase. Arteriosclerosis, Thrombosis, and Vascular Biology, 28(9), 1627–1633.PubMedCrossRef

125.

Du, X., Edelstein, D., Obici, S., Higham, N., Zou, M. H., & Brownlee, M. (2006). Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. The Journal of Clinical Investigation, 116(4), 1071–1080.PubMedCrossRef

126.

Shen, X., Zheng, S., Metreveli, N. S., & Epstein, P. N. (2006). Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes, 55(3), 798–805.PubMedCrossRef

127.

Otero, P., Bonet, B., Herrera, E., & Rabano, A. (2005). Development of atherosclerosis in the diabetic BALB/c mice. Prevention with vitamin E administration. Atherosclerosis, 182(2), 259–265.PubMedCrossRef

128.

Zhang, Y., Wada, J., Hashimoto, I., et al. (2006). Therapeutic approach for diabetic nephropathy using gene delivery of translocase of inner mitochondrial membrane 44 by reducing mitochondrial superoxide production. Journal of the American Society of Nephrology, 17(4), 1090–1101.PubMedCrossRef

129.

DeRubertis, F. R., Craven, P. A., & Melhem, M. F. (2007). Acceleration of diabetic renal injury in the superoxide dismutase knockout mouse: effects of tempol. Metabolism, 56(9), 1256–1264.PubMedCrossRef

130.

Kowluru, R. A., Kowluru, V., Xiong, Y., & Ho, Y. S. (2006). Overexpression of mitochondrial superoxide dismutase in mice protects the retina from diabetes-induced oxidative stress. Free Radical Biology & Medicine, 41(8), 1191–1196.CrossRef

131.

Vincent, A. M., Russell, J. W., Sullivan, K. A., et al. (2007). SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Experimental Neurology, 208(2), 216–227.PubMedCrossRef

132.

Kurash, J. K., Lei, H., Shen, Q., et al. (2008). Methylation of p53 by Set7/9 mediates p53 acetylation and activity in vivo. Molecular Cell, 29(3), 392–400.PubMedCrossRef

Title: Chromatin Modifications Associated with Diabetes
Authors: Samuel T. Keating
Assam El-Osta
Publication date: 01-08-2012
Publisher: Springer US
Published in: Journal of Cardiovascular Translational Research / Issue 4/2012
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-012-9380-9

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Chromatin Modifications Associated with Diabetes

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2012

Oxidative Stress, Nox Isoforms and Complications of Diabetes—Potential Targets for Novel Therapies

MicroRNAs and Diabetic Complications

Haptoglobin Genotype and Its Role in Diabetic Cardiovascular Disease

Cardiac Responses to the Intrapericardial Delivery of Metoprolol: Targeted Delivery Compared to Intravenous Administration

Proteomics and Systems Biology for Understanding Diabetic Nephropathy

Erratum to: Cardiovascular Disease Risk in Young People with Type 1 Diabetes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page